Collection and Processing: Amotosalen Reduction
Collection & Processing: Reduction of Residual Amotosalen
When illumination is complete, the treated platelets or plasma are exposed to a Compound Adsorption Device, or 'CAD'. The CAD is composed of beads designed to reduce residual amotosalen to extremely low levels by adsorbing it from solution. For platelets, a 4 – 16 hour incubation range allows blood centers the flexibility to accommodate either same-day processing and release, or to allow the CAD step to continue overnight. The plasma CAD is a flow-through system that can be completed in approximately 20 minutes.
 |
Amotosalen is reduced to extremely low levels after adsorption into the CAD. The illuminated platelets or plasma are drained into the CAD by gravity flow. Platelets are incubated on a platelet shaker for 4 to 16 hours to complete the adsorption step. Plasma flows through a CAD disk directly into the final plasma storage containers. |
Implementation and Use page 5 of 7 
©
Cerus Corporation. All Rights Reserved.
Use of the INTERCEPT Blood System in the United States is limited by Federal law to investigational use. If you are a resident of the U.S., please click here.
The information on this site is not country-specific, and may contain information that is outside the approved indications for the country in which you are located. The INTERCEPT Blood System is CE marked for use with platelets and plasma.
Website design by NetPilot Web Solutions
Use of the INTERCEPT Blood System in the United States is limited by Federal law to investigational use. If you are a resident of the U.S., please click here.
The information on this site is not country-specific, and may contain information that is outside the approved indications for the country in which you are located. The INTERCEPT Blood System is CE marked for use with platelets and plasma.
Website design by NetPilot Web Solutions